News and Trends 19 Apr 2018 “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […] April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2018 Finnish Rapid Molecular Diagnostic Test Enters European Market Mobidiag, a Finnish biotech, has launched a diagnostic test that can rapidly detect the most common disease-causing microbes in the gut. The test can help manage infections more effectively at an earlier stage. Mobidiag has launched a molecular diagnostic test on the European market that checks patient samples for numerous bacterial targets, including the most […] April 18, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 18 Apr 2018 What Lies Ahead for European Cell and Gene Therapies? Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […] April 18, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2018 How Low Can the Price of a Next Generation DNA Sequencer Go? The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market. Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for […] April 17, 2018 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 16 Apr 2018 Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves’ disease, one of the most common autoimmune diseases. Apitope has obtained positive clinical results indicating its treatment for Graves’ disease is safe and well-tolerated. A common autoimmune disease affecting the thyroid, Graves’ disease occurs when a patient’s immune system […] April 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2018 French Double-Hormone Diabetes Treatment to be Tested in Humans for the First Time Adocia, a French biotech, will initiate a Phase I clinical study to test a diabetes treatment that maximizes the effect of two blood sugar-lowering hormones. Adocia will start a Phase I clinical trial to test the safety and tolerability of its BioChaperone Pramlintide Insulin treatment to control blood sugar levels after a meal in type 1 […] April 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Apr 2018 This Israeli Biotech Targets Protein Translation to Fight Disease Today, we’re taking a look at Anima Biotech, an Israeli company that is developing a new class of drugs that target protein translation to combat a range of diseases, including lung fibrosis, cancer, and Huntington’s disease. Mission: Since 2010, Anima Biotech has been targeting disease-causing proteins with a new class of drugs that control protein translation. […] April 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2018 British Biotech Raises £29M Round to Fight Lung Disease Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development. Enterprise Therapeutics, a British biotech, has raised £29M (€33M) in Series B from several investors including Forbion, one of the most active European life science VCs. In Enterprise, Forbion has found a replacement in its portfolio for the Dutch […] April 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 12 Apr 2018 Graphene Skin Patch Measures Blood Sugar Without a Needle Researchers in the UK have developed a skin patch that measures blood sugar levels without the prick of a needle by pulling fluid out from between hair follicles. The technology could be used for both type 1 and type 2 diabetes patients. Diabetes is a major global health problem, with the World Health Organization stating 422 […] April 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 Alexion Acquires Swedish Treatment for Wilson’s Disease Alexion Pharmaceutical intends to buy Wilson Therapeutics for nearly $1Bn. Wilson is developing a first-in-class treatment for Wilson’s disease, a rare disorder that can lead to severe liver and brain damage. Alexion Pharmaceuticals, one of the most successful companies in rare diseases and known for selling one of the most expensive drugs in the world, […] April 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 Dutch Organs-on-Chips Raises $20.5M in Series B Financing MIMETAS, a Dutch biotech, has raised a Series B financing round to continue developing its organ-on-a-chip platform, which could remove the need to use animals in preclinical drug testing. MIMETAS, based in Leiden, has secured $20.5M (€17M) in Series B financing from investors in Asia and Europe. The company will use the funding to develop its organ-on-a-chip […] April 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 French CAR-T Developer Raises $164M Despite a Challenging Road Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […] April 11, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email